By Dean Seal
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
The biotechnology company said Monday that DNL343 didn't meet the primary endpoint of slowing disease progression as compared with a placebo. Secondary endpoints measuring muscle strength and respiratory function weren't statistically different between active and placebo groups.
The treatment was found to be safe and well tolerated, and further analyses are anticipated later this year.
"Though the initial top-line clinical results of this trial were not what we hoped, the data collected is valuable in helping to understand the next stage of ALS research," said Merit Cudkowicz, the principal investigator of the trial.
Shares fell 7.7% to $18.30 in after-market trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 06, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.